918 related articles for article (PubMed ID: 23244811)
1. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
Hawton A; Green C; Telford C; Zajicek J; Wright D
Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
[TBL] [Abstract][Full Text] [Related]
2. Using the Fatigue Severity Scale to inform healthcare decision-making in multiple sclerosis: mapping to three quality-adjusted life-year measures (EQ-5D-3L, SF-6D, MSIS-8D).
Goodwin E; Hawton A; Green C
Health Qual Life Outcomes; 2019 Aug; 17(1):136. PubMed ID: 31382960
[TBL] [Abstract][Full Text] [Related]
3. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
4. The use of multiple sclerosis condition-specific measures to inform health policy decision-making: mapping from the MSWS-12 to the EQ-5D.
Hawton A; Green C; Telford CJ; Wright DE; Zajicek JP
Mult Scler; 2012 Jun; 18(6):853-61. PubMed ID: 22108867
[TBL] [Abstract][Full Text] [Related]
5. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China.
Yang Q; Yu XX; Zhang W; Li H
Health Qual Life Outcomes; 2019 Oct; 17(1):153. PubMed ID: 31615531
[TBL] [Abstract][Full Text] [Related]
6. Mapping the SRS-22r questionnaire onto the EQ-5D-5L utility score in patients with adolescent idiopathic scoliosis.
Wong CKH; Cheung PWH; Samartzis D; Luk KD; Cheung KMC; Lam CLK; Cheung JPY
PLoS One; 2017; 12(4):e0175847. PubMed ID: 28414745
[TBL] [Abstract][Full Text] [Related]
7. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):89-96. PubMed ID: 30173585
[TBL] [Abstract][Full Text] [Related]
8. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.
Teckle P; McTaggart-Cowan H; Van der Hoek K; Chia S; Melosky B; Gelmon K; Peacock S
Health Qual Life Outcomes; 2013 Dec; 11():203. PubMed ID: 24289488
[TBL] [Abstract][Full Text] [Related]
9. Mapping QLQ-C30 Onto EQ-5D-5L and SF-6D-V2 in Patients With Colorectal and Breast Cancer From a Developing Country.
Yousefi M; Nahvijou A; Sari AA; Ameri H
Value Health Reg Issues; 2021 May; 24():57-66. PubMed ID: 33508752
[TBL] [Abstract][Full Text] [Related]
10. Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.
Whitehurst DG; Norman R; Brazier JE; Viney R
Value Health; 2014 Jul; 17(5):570-7. PubMed ID: 25128050
[TBL] [Abstract][Full Text] [Related]
11. Validation and comparison of EuroQol and short form 6D in chronic prostatitis patients.
Zhao FL; Yue M; Yang H; Wang T; Wu JH; Li SC
Value Health; 2010 Aug; 13(5):649-56. PubMed ID: 20412540
[TBL] [Abstract][Full Text] [Related]
12. Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia.
Abdin E; Chong SA; Seow E; Verma S; Tan KB; Subramaniam M
Qual Life Res; 2019 Jan; 28(1):177-186. PubMed ID: 30382480
[TBL] [Abstract][Full Text] [Related]
13. The development of a model for translation of the Neck Disability Index to utility scores for cost-utility analysis in cervical disorders.
Richardson SS; Berven S
Spine J; 2012 Jan; 12(1):55-62. PubMed ID: 22209244
[TBL] [Abstract][Full Text] [Related]
14. Health Utilities for Multiple Sclerosis.
Hawton A; Green C
Value Health; 2016 Jun; 19(4):460-8. PubMed ID: 27325338
[TBL] [Abstract][Full Text] [Related]
15. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
Liu T; Li S; Wang M; Sun Q; Chen G
Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
[TBL] [Abstract][Full Text] [Related]
16. Scale characteristics and mapping accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in patients with rheumatoid arthritis.
Wolfe F; Michaud K; Wallenstein G
J Rheumatol; 2010 Aug; 37(8):1615-25. PubMed ID: 20551106
[TBL] [Abstract][Full Text] [Related]
17. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.
McCrone P; Patel A; Knapp M; Schene A; Koeter M; Amaddeo F; Ruggeri M; Giessler A; Puschner B; Thornicroft G
J Ment Health Policy Econ; 2009 Mar; 12(1):27-31. PubMed ID: 19346564
[TBL] [Abstract][Full Text] [Related]
18. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
[TBL] [Abstract][Full Text] [Related]
19. Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People's Quality of Life Brief Questionnaire (OPQoL-Brief) Scores.
Kaambwa B; Ratcliffe J
Patient; 2018 Feb; 11(1):39-54. PubMed ID: 28623629
[TBL] [Abstract][Full Text] [Related]
20. Estimating EQ-5D values from the Neck Disability Index and numeric rating scales for neck and arm pain.
Carreon LY; Bratcher KR; Das N; Nienhuis JB; Glassman SD
J Neurosurg Spine; 2014 Sep; 21(3):394-9. PubMed ID: 24905392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]